These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 28802074)

  • 21. Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls.
    Heebøll S; Poulsen MK; Ornstrup MJ; Kjær TN; Pedersen SB; Nielsen S; Grønbæk H; Handberg A
    Int J Obes (Lond); 2017 Feb; 41(2):262-267. PubMed ID: 27916988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glutamate-Serine-Glycine Index: A Novel Potential Biomarker in Pediatric Non-Alcoholic Fatty Liver Disease.
    Leonetti S; Herzog RI; Caprio S; Santoro N; Tricò D
    Children (Basel); 2020 Dec; 7(12):. PubMed ID: 33291552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD).
    Mager DR; Iñiguez IR; Gilmour S; Yap J
    JPEN J Parenter Enteral Nutr; 2015 Jan; 39(1):73-84. PubMed ID: 23976771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in non-obese Hispanic patients: a pilot study.
    Cortés V; Quezada N; Uribe S; Arrese M; Nervi F
    Lipids Health Dis; 2017 Jun; 16(1):129. PubMed ID: 28666456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P.
    Caviglia GP; Rosso C; Armandi A; Gaggini M; Carli F; Abate ML; Olivero A; Ribaldone DG; Saracco GM; Gastaldelli A; Bugianesi E
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266488
    [No Abstract]   [Full Text] [Related]  

  • 26. miRNA-103: molecular link between insulin resistance and nonalcoholic fatty liver disease.
    Xu Q; Li Y; Shang YF; Wang HL; Yao MX
    World J Gastroenterol; 2015 Jan; 21(2):511-6. PubMed ID: 25593466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic Fatty Liver Disease Relationship with Metabolic Syndrome in Class III Obesity Individuals.
    Cordeiro A; Pereira SE; Saboya CJ; Ramalho A
    Biomed Res Int; 2015; 2015():839253. PubMed ID: 26120587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
    El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
    Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance.
    Yang KC; Hung HF; Lu CW; Chang HH; Lee LT; Huang KC
    Sci Rep; 2016 Jun; 6():27034. PubMed ID: 27246655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
    Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
    Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents.
    McCormack SE; Shaham O; McCarthy MA; Deik AA; Wang TJ; Gerszten RE; Clish CB; Mootha VK; Grinspoon SK; Fleischman A
    Pediatr Obes; 2013 Feb; 8(1):52-61. PubMed ID: 22961720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation With Insulin Resistance, Inflammation, and Liver Histology.
    Boga S; Alkim H; Koksal AR; Bayram M; Ozguven MB; Ergun M; Neijmann ST; Ozgon G; Alkim C
    J Investig Med; 2015 Oct; 63(7):871-7. PubMed ID: 26244718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternation of plasma fatty acids composition and desaturase activities in children with liver steatosis.
    Hua MC; Su HM; Yao TC; Kuo ML; Lai MW; Tsai MH; Huang JL
    PLoS One; 2017; 12(7):e0182277. PubMed ID: 28759573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced circulating levels of sTWEAK are associated with NAFLD and may affect hepatocyte triglyceride accumulation.
    Lozano-Bartolomé J; Llauradó G; Rodriguez MM; Fernandez-Real JM; Garcia-Fontgivell JF; Puig J; Maymó-Masip E; Vendrell J; Chacón MR
    Int J Obes (Lond); 2016 Sep; 40(9):1337-45. PubMed ID: 27121253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations among the plasma amino acid profile, obesity, and glucose metabolism in Japanese adults with normal glucose tolerance.
    Takashina C; Tsujino I; Watanabe T; Sakaue S; Ikeda D; Yamada A; Sato T; Ohira H; Otsuka Y; Oyama-Manabe N; Ito YM; Nishimura M
    Nutr Metab (Lond); 2016; 13():5. PubMed ID: 26788116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body mass index and waist circumference in non-alcoholic fatty liver disease.
    Rocha R; Cotrim HP; Carvalho FM; Siqueira AC; Braga H; Freitas LA
    J Hum Nutr Diet; 2005 Oct; 18(5):365-70. PubMed ID: 16150132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-Alcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: Role of Circulating Branched-Chain Amino Acids.
    van den Berg EH; Flores-Guerrero JL; Gruppen EG; de Borst MH; Wolak-Dinsmore J; Connelly MA; Bakker SJL; Dullaart RPF
    Nutrients; 2019 Mar; 11(3):. PubMed ID: 30917546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?
    Shabani P; Naeimi Khaledi H; Beigy M; Emamgholipour S; Parvaz E; Poustchi H; Doosti M
    PLoS One; 2015; 10(3):e0118650. PubMed ID: 25767880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.